Ozono Kazutaka, Kawakami Fumi, Mikami Yoshiki
Department of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto, Japan.
Department of Surgical Pathology, Japan Community Health Care Organization Kumamoto General Hospital, Kumamoto, Japan.
Obstet Gynecol Sci. 2025 Jan;68(1):79-89. doi: 10.5468/ogs.24236. Epub 2024 Dec 18.
To evaluate the diagnostic utility and limitations of routine p16 and Ki-67 immunohistochemistry (IHC) in detecting high-grade squamous intraepithelial lesions (HSILs) in the uterine cervix.
We reviewed 2,061 cervical biopsy records, including 271 morphologically indeterminate squamous lesions, evaluated using p16/Ki-67 IHC for HSIL detection or exclusion. HSIL was diagnosed based on p16 positivity and a high Ki-67 labeling index (Ki-LI). In cases that remained inconclusive after IHC, follow-up histological and/or cytological outcomes were assessed.
p16/Ki-67 IHC established a definitive diagnosis of either HSIL or non-HSIL in 74.2% (201/271) of morphologically indeterminate cases, whereas 25.8% (70/271) remained inconclusive. p16/Ki-67 IHC contributed to diagnosing 120 HSIL cases, representing 11.9% (120/1,011) of all HSILs cases and 44.3% (120/271) of morphologically indeterminate cases. Among the 70 inconclusive cases, 58 had available follow-up data, of which 22 were subsequently diagnosed with HSIL, including 12 within 1 month of the initial biopsy. HSIL outcomes were more frequent in cases with suspicious HSIL on the initial biopsy (66.7% [12/18]). Based on the p16/Ki-LI status observed in the initial biopsy, patients with HSIL outcomes were categorized into three groups: p16-positive/low Ki-LI (54.2% [13/24]), p16-negative/high Ki-LI (50.0% [5/10]), and p16-negative/low Ki-LI (16.7% [4/24]). Multiple comparisons revealed a significant difference between the p16-positive/low Ki-LI and p16-negative/low Ki-LI groups (Benjamini-Yekutieli adjusted P=0.0435), while other comparisons were not significant.
p16/Ki-67 IHC significantly improved the diagnostic performance for HSIL. In cases that remain inconclusive after IHC, IHC-based risk stratification offers a valuable approach for surveillance, thus mitigating delays in HSIL diagnosis.
评估常规p16和Ki-67免疫组织化学(IHC)在检测子宫颈高级别鳞状上皮内病变(HSIL)中的诊断效用及局限性。
我们回顾了2061份宫颈活检记录,其中包括271例形态学上无法确定的鳞状病变,使用p16/Ki-67 IHC评估以检测或排除HSIL。基于p16阳性和高Ki-67标记指数(Ki-LI)诊断HSIL。对于IHC后仍无法确诊的病例,评估后续的组织学和/或细胞学结果。
p16/Ki-67 IHC在74.2%(201/271)形态学上无法确定的病例中明确诊断为HSIL或非HSIL,而25.8%(70/271)仍无法确诊。p16/Ki-67 IHC有助于诊断120例HSIL病例,占所有HSIL病例的11.9%(120/1011),占形态学上无法确定病例的44.3%(120/271)。在70例无法确诊的病例中,58例有可用的随访数据,其中22例随后被诊断为HSIL,包括12例在初次活检后1个月内确诊。初次活检时有可疑HSIL的病例中HSIL结局更为常见(66.7%[12/18])。根据初次活检中观察到的p16/Ki-LI状态,将有HSIL结局的患者分为三组:p16阳性/低Ki-LI(54.2%[13/24])、p16阴性/高Ki-LI(50.0%[5/10])和p16阴性/低Ki-LI(16.7%[4/24])。多重比较显示p16阳性/低Ki-LI组和p16阴性/低Ki-LI组之间存在显著差异(Benjamini-Yekutieli校正P=0.0435),而其他比较无显著差异。
p16/Ki-67 IHC显著提高了HSIL的诊断性能。对于IHC后仍无法确诊的病例,基于IHC的风险分层为监测提供了一种有价值的方法,从而减少HSIL诊断的延迟。